Work

Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease

Year: 2014

Type: review

Source: Clinical Gastroenterology and Hepatology

DOI: 10.1016/j.cgh.2014.02.016

Authors: Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Institutions: Inserm, Centre Hospitalier Régional et Universitaire de Nancy, Nutrition-Génétique et Exposition aux Risques Environnementaux, Université Henri Poincaré, Université de Lorraine, University of California San Diego

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Merck, Novartis, Roche, Gilead Sciences, Orexigen Therapeutics, Optimer Pharmaceuticals, Shire, Genentech, UCB Pharma

OpenAlex ID: W2033081617

FWCI: 4.403

Cites: 150

Cited by: 267

Related to: 10